Subscribe to our Newsletters !!
Drug quality is defined not only how a drug is man
It is undeniable what the history different has wi
The journey and merging of sperm and egg cells is
This year, the Hamburg based life sciences company
Cipla Limited (BSE: 5
Since it’s an ingredient in so many foods, you h
In a world constantly in motion, Microbioz India r
Aurobindo Pharma on Tuesday announced collaboration with the Biotechnology Industry Research Assistance Council (BIRAC), set up by the Department of Biotechnology for the development of COVID-19 vaccine. Aurobindo Pharma said it is developing a vaccine for COVID-19 through its wholly-owned US subsidiary, Auro Vaccines.
“Aurobindo is in the process of preparing a state-of-art manufacturing facility for viral vaccines that will be used to produce the COVID-19 vaccine along with other viral vaccines. The plant will comply with international standards. The company”s COVID-19 vaccine development is going according to plan,” the filing added.
Commenting on the collaboration, Aurobindo Pharma Managing Director N Govindarajan said,” It’s a matter of immense pride that BIRAC has put its trust on the vaccine capabilities. The senior leadership of Aurobindo and Auro Vaccines has extensive experience in development, manufacturing and commercialization of many vaccines.”
Department of Biotechnology Secretary and BIRAC Chairperson Renu Swarup said the partnership with Aurobindo is to serve the country”s need for a vaccine to fight this pandemic.
“The government is focussed on developing an ecosystem that nurtures and encourages new product innovation to deal with the most relevant issues to our society,” Swarup added.
Bharat Biotech, Serum Institute, Zydus Cadila, Panacea Biotec, Indian Immunologicals, Mynvax and Biological E are among the pharma firms in India working on the coronavirus vaccine.
